Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.
- DOI
- 10.1080/14796694.2026.2674970
- Published
- 2026 Jun
- Container
- Future oncology (London, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.1080/14796694.2026.2674970,
title = {Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.},
author = {Rugo HS and Layman RM and Lynce F and Liu X and Li B and McRoy L and Cohen AB and Estevez M and Curigliano G and Brufsky A},
year = {2026},
journal = {Future oncology (London, England)},
doi = {10.1080/14796694.2026.2674970},
url = {https://doi.org/10.1080/14796694.2026.2674970}
}RIS
TY - JOUR TI - Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary. AU - Rugo HS AU - Layman RM AU - Lynce F AU - Liu X AU - Li B AU - McRoy L AU - Cohen AB AU - Estevez M AU - Curigliano G AU - Brufsky A PY - 2026 JO - Future oncology (London, England) DO - 10.1080/14796694.2026.2674970 UR - https://doi.org/10.1080/14796694.2026.2674970 ER -
APA
HS, R., RM, L., F, L., X, L., B, L., L, M., AB, C., M, E., G, C., & A, B. (2026). Comparison of survival outcomes for people with HR+/HER2- metastatic breast cancer who received palbociclib, ribociclib, or abemaciclib with an aromatase inhibitor: a plain language summary.. Future oncology (London, England). https://doi.org/10.1080/14796694.2026.2674970
Source records
- pubmed · retrieved 2026-09-27T09:30:02.157Z